|
1
|
Menghini D, Costanzo F and Vicari S:
Relationship between brain and cognitive processes in Down
syndrome. Behav Genet. 41:381–393. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Piovesan A, Caracausi M, Antonaros F,
Pelleri MC and Vitale L: GeneBase 1.1: A tool to summarize data
from NCBI gene datasets and its application to an update of human
gene statistics. Database (Oxford). 2016(baw153)2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Letourneau A and Antonarakis SE: Genomic
determinants in the phenotypic variability of Down syndrome. Prog
Brain Res. 197:15–28. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
European Commission: EUROCAT
Data-Prevalence and Tables. Accessible at: https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-data/prevalence_en.
|
|
5
|
Dolk H, Loane M, Garne E, De Walle H,
Queisser-Luft A, De Vigan C, Addor MC, Gener B, Haeusler M, Jordan
H, et al: Trends and geographic inequalities in the prevalence of
Down syndrome in Europe, 1980-1999. Rev Epidemiol Sante Publique 53
Spec No. 2:2S87–2S95. 2005.PubMed/NCBI
|
|
6
|
Morris JK, Garne E, Wellesley D, Addor MC,
Arriola L, Barisic I, Beres J, Bianchi F, Budd J, Dias CM, et al:
Major congenital anomalies in babies born with Down syndrome: A
EUROCAT population-based registry study. Am J Med Genet A.
164A:2979–2986. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kagan KO, Wright D, Baker A, Sahota D and
Nicolaides KH: Screening for trisomy 21 by maternal age fetal
nuchal translucency thickness, free beta-human chorionic
gonadotropin and pregnancy-associated plasma protein-A. Ultrasound
Obstet Gynecol. 31:618–624. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Nicolaides KH: Nuchal translucency and
other first-trimester sonographic markers of chromosomal
abnormalities. Am J Obstet Gynecol. 191:45–67. 2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kagan KO, Staboulidou I, Cruz J, Wright D
and Nicolaides KH: Two-stage first-trimester screening for trisomy
21 by ultrasound assessment and biochemical testing. Ultrasound
Obstet Gynecol. 36:542–547. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Colton T: Statistics in medicine. Little
Brown and Company, New York, pp19-20, 1974.
|
|
11
|
Lanzoni M, Kinsner-Ovaskainen A, Morris J
and Martin S: EUROCAT-Surveillance of Congenital Anomalies in
Europe: Epidemiology of Down syndrome 1990-2014. La Placa G and
Spirito L (eds). Publications Office of the European Union,
Luxembourg, 2019.
|
|
12
|
Heidari R, Akbariqomi M, Motevaseli E,
Omrani MD, Kooshki H, Shamshiri AR, Shafei S, Absalan M, Mazlomi
MA, Saleh Gargari S and Tavoosidana G: Performance and predictive
value of first Trimester screening markers for down syndrome in
Iranian pregnancies. J Family Reprod Health. 12:121–128.
2018.PubMed/NCBI
|
|
13
|
Royère D: Working Group Trisomy 21
Screening. The impact of introducing combined first-trimester
trisomy 21 screening in the French population. Eur J Public Health.
26:492–497. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Cignini P, Maggio Savasta L, Gulino FA,
Vitale SG, Mangiafico L, Mesoraca A and Giorlandino C: Predictive
value of pregnancy-associated plasma protein-A (PAPP-A) and free
beta-hCG on fetal growth restriction: Results of a prospective
study. Arch Gynecol Obstet. 293:1227–1233. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Stefanovic V, Äyräs O, Eronen M, Paavonen
J and Tikkanen M: Clinical utility of nuchal translucency
screening. Res Rep Neonatol. 4:169–176. 2014.
|
|
16
|
Goetzinger KR, Singla A, Gerkowicz S,
Dicke JM, Gray DL and Odibo AO: Predicting the risk of
pre-eclampsia between 11 and 13 weeks' gestation by combining
maternal characteristics and serum analytes, PAPP-A and free β-hCG.
Prenat Diagn. 30:1138–1142. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Conover CA: Key questions and answers
about pregnancy- associated plasma protein-A. Trends Endrocrinol
Metab. 23:242–249. 2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Monget P and Oxvig C: PAPP-A and the IGF
system. Ann Endocrinol (Paris). 77:90–96. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012.PubMed/NCBI View
Article : Google Scholar
|
|
20
|
Conover CA and Oxvig C: PAPP-A and cancer.
J Mol Endocrinol. 61:T1–T10. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hendriks E, MacNaughton H and MacKenzie
MC: First trimester bleeding: Evaluation and management. Am Fam
Physician. 99:166–174. 2019.PubMed/NCBI
|
|
22
|
Tang Y, Luo H, Mu D, Yang T, Zhu Q, Yang F
and Liu G: Early diagnosis of trisomy 21, trisomy 18 and trisomy 13
using nuchal translucency thickness and ductus venosus blood flow
waveform in West China. Mol Med Rep. 19:1349–1355. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang J and Zhang B: Second-generation
non-invasive high-throughput DNA sequencing technology in the
screening of Down's syndrome in advanced maternal age women. Biomed
Rep. 4:715–718. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Qiang R, Cai N, Wang X, Wang L, Cui K,
Wang W, Wang X and Li X: Detection of trisomies 13,18 and 21 using
non-invasive prenatal tasting. Exp Ther Med. 13:2304–2310.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Patil M, Panchanadikar TM and Wagh G:
Variation of PAPP-A level in the first trimester of pregnancy and
its clinical outcome. J Obstet Gynaecol India. 64:116–119.
2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lau H, Amarasekara C and Uppal T: Low
PAPP-A: What are the clinical implications? Australas J Ultrasound
Med. 15:26–28. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Antsaklis P, Fasoulakis Z, Theodora M,
Diakosavvas M and Kontomanolis EN: Association of low maternal
pregnancy-associated plasma protein a with adverse perinatal
outcome. Cureus. 11(e4912)2019.PubMed/NCBI View Article : Google Scholar
|
